Adrenocortical carcinoma: Clinicopathological features, prognostic factors and outcome

Urologia Internationalis

Volumn 90, Issue 4, 2013, Pages 435-438

  Keskin, Serkan ^a   Taş, Faruk ^a   Vatansever, Sezai ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Adrenocortical carcinoma; Clinicopathological characteristics; Survival rates

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MITOTANE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SKIN METASTASIS; SURVIVAL TIME; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CAUSE OF DEATH; CLINICAL EVALUATION; CONTROLLED STUDY; CUSHING SYNDROME; DISEASE COURSE; DISTANT METASTASIS; FOLLOW UP; HYPERALDOSTERONISM; INOPERABLE CANCER; LYMPH NODE METASTASIS; SEX DIFFERENCE; TUMOR VOLUME; VIRILIZATION;

ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL CARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CISPLATIN; ETOPOSIDE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84879133606     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000345489     Document Type: Article

References (24)

1. Vaughan ED Jr: Diseases of the adrenal gland. Med Clin North Am 2004; 88: 443-466.
2. Roman S: Adrenocortical carcinoma. Curr Opin Oncol 2006; 18: 36-42.
3. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C: Adrenocortical carcinomas: Surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 2001; 25: 891-897.
4. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, Sturgeon C: Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors. Cancer 2008; 113: 3130-3136.
5. Nishida S, Itoh N, Sasao T, Masumori N, Taguchi K, Tsukamoto T: Adrenocortical carcinoma: Retrospective study of 14 patients experienced at a single institution over 34 years. Int J Urol 2007; 14: 581-584.
6. Gomez-Rivera F, Medina-Franco H, Arch-Ferrer JE, Heslin MJ: Adrenocortical carcinoma: A single institution experience. Am Surg 2005; 71: 90-94.
7. Tauchmanova L, Colao A, Marzano LA, Sparano L, Camera L, Rossi A, Palmieri G, Marzano E, Salvatore M, Pettinato G, Lombardi G, Rossi R: Adrenocortical carcinomas: Twelve-year prospective experience. World J Surg 2004; 28: 896-903.
8. Vassilopoulou-Sellin R, Schultz PN: Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001; 92: 1113-1121.
9. Tucci S Jr, Martins AC, Suaid HJ, Cologna AJ, Reis RB: The impact of tumor stage on prognosis in children with adrenocortical carcinoma. J Urol 2005; 174: 2338-2342.
10. Schulick RD, Brennan MF: Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999; 6: 719-726.
11. Dong D, Li H, Yan W, Ji Z, Mao Q: Surgical management and clinical prognosis of adrenocortical carcinoma. Urol Int 2012; 88: 400-404.
12. Gomha AM, Osman Y, El-Mekresh M, Abou El-Ghar M, Eraky I: Diagnosis and treatment of adrenal tumors: A single-center experience with 238 cases. Urol Int 2009; 83: 433-437.
13. Osman Y, El-Mekresh M, Gomha AM, Mohsen T, Taha N, Hussein N, Eraky I: Percutaneous adrenal biopsy for indeterminate adrenal lesion: Complications and diagnostic accuracy. Urol Int 2010; 84: 315-318.
14. Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C, Riedmiller H, Spahn M, Weismann D, Hahner S, Fassnacht M: Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: Surgical and oncologic outcome in 152 patients. Eur Urol 2010; 58: 609-615.
15. Gaujoux S, Brennan MF: Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery 2012; 152: 123-132.
16. Porpiglia F, Miller BS, Manfredi M, Fiori C, Doherty GM: A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer 2011; 2: 372-377.
17. Bellantone R, Ferrante A, Boscherini M, Lombardi CP, Crucitti P, Crucitti F, Favia G, Borrelli D, Boffi L, Capussotti L, Carbone G, Casaccia M, Cavallaro A, Del Gaudio A, Dettori G, Di Giovanni V, Mazziotti A, Marrano D, Masenti E, Miccoli P, Mosca F, Mussa A, Petronio R, Piat G, Marazano L, et al: Role of reoperation in recurrence of adrenal cortical carcinoma: Results from 188 cases collected in the Italian national registry for adrenal cortical carcinoma. Surgery 1997; 122: 1212-1218.
18. Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, Libutti SK, Fojo T, Schrump DS, Avital I: Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol 2012; 105: 709-713.
19. Veytsman I, Nieman L, Fojo T: Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 2009; 27: 4619-4629.
20. Didolkar MS, Bescher RA, Elias EG, Moore RH: Natural history of adrenal cortical carcinoma: A clinicopathologic study of 42 patients. Cancer 1981; 47: 2153-2161.
21. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356: 2372-2380.
22. Icard P, Chapuis Y, Andreassian B, Bernard A, Proye C: Adrenocortical carcinoma in surgically treated patients: A retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992; 112: 972-979.
23. Wooten MD, King DK: Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993; 72: 3145-3155.
24. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardiere C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Muller HH, Skogseid B: Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366: 2189-2197.